The estimated Net Worth of Kevin M. Lalande is at least $11.9 Million dollars as of 13 June 2022. Mr. Lalande owns over 222,000 units of Molecular Templates Inc stock worth over $304,140 and over the last 7 years he sold MTEM stock worth over $11,478,000. In addition, he makes $160,552 as Independent Director at Molecular Templates Inc.
Sign up
Mr. Lalande MTEM stock SEC Form 4 insiders trading
Kevin has made over 3 trades of the Molecular Templates Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 222,000 units of MTEM stock worth $197,580 on 13 June 2022.
The largest trade he's ever made was selling 500,000 units of Molecular Templates Inc stock on 16 September 2020 worth over $6,525,000. On average, Kevin trades about 85,167 units every 63 days since 2017. As of 13 June 2022 he still owns at least 222,000 units of Molecular Templates Inc stock.
You can see the complete history of Mr. Lalande stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Lalande biography
Kevin M. Lalande serves as Independent Director of the Company. Mr. Lalande served on the board of directors of Private Molecular since 2009. Mr. Lalande is a founder and Managing Director of Santé Ventures, a venture capital firm. Prior to founding Santé Ventures in 2006, Mr. Lalande spent seven years with Austin Ventures. Before joining Austin Ventures, Mr. Lalande was a management consultant with McKinsey & Company. Mr. Lalande holds a B.S. in Electrical and Computer Engineering from Brigham Young University and an M.B.A. with Highest Distinction from the Harvard Business School. Our Board has concluded that Mr. Lalande should serve as a director of the Company based on his substantial experience as a venture capitalist and as a director of a number of privately-held companies.
What is the salary of Kevin Lalande?
As the Independent Director of Molecular Templates Inc, the total compensation of Kevin Lalande at Molecular Templates Inc is $160,552. There are 10 executives at Molecular Templates Inc getting paid more, with Eric Poma having the highest compensation of $1,733,740.
How old is Kevin Lalande?
Kevin Lalande is 47, he's been the Independent Director of Molecular Templates Inc since 2017. There are 13 older and 6 younger executives at Molecular Templates Inc. The oldest executive at Molecular Templates Inc is David Hoffmann, 75, who is the Independent Director.
What's Kevin Lalande's mailing address?
Kevin's mailing address filed with the SEC is C/O SANTE VENTURES, 201 WEST 5TH STREET, SUITE 1500, AUSTIN, TX, 78701.
Insiders trading at Molecular Templates Inc
Over the last 7 years, insiders at Molecular Templates Inc have traded over $22,993,582 worth of Molecular Templates Inc stock and bought 14,744,530 units worth $82,519,716 . The most active insiders traders include Target N Vbb Biotech Ag Bio..., David Hirsch, and Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of $532,718. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth $587,500.
What does Molecular Templates Inc do?
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
What does Molecular Templates Inc's logo look like?
Complete history of Mr. Lalande stock trades at Molecular Templates Inc
Molecular Templates Inc executives and stock owners
Molecular Templates Inc executives and other stock owners filed with the SEC include:
-
Eric Poma,
Chief Executive Officer, Chief Scientific Officer, Director -
Roger Waltzman,
Chief Medical Officer -
Jason Kim,
President, Chief Operating Officer -
Adam Cutler,
Chief Financial Officer, Treasurer, Secretary -
Dr. Eric E. Poma,
CEO, Chief Scientific Officer & Director -
Dr. Roger J. Waltzman M.B.A., M.D.,
Chief Medical Officer -
Jason S Kim,
Pres & COO -
Dr. Roger J. Waltzman,
Chief Medical Officer -
Corazon Sanders,
Independent Director -
Harold Selick,
Chairman of the Board -
Kevin Lalande,
Independent Director -
David Hirsch,
Independent Director -
David Hoffmann,
Independent Director -
Scott Morenstein,
Independent Director -
Jonathan Lanfear,
Independent Director -
Michael Dowd,
Sr. VP of Project & Alliance Management -
Megan C. Filoon,
Gen. Counsel & Sec. -
Dr. Nenad Sarapa M.D., M.S.,
Sr. VP of Clinical Devel. -
Dr. Jen-Sing Liu Ph.D.,
Exec. VP of Manufacturing -
Dr. Erin Willert Ph.D.,
Exec. VP of R&D -
Dr. Jack Higgins Ph.D.,
Exec. VP of Operations & Head of Manufacturing -
Kurt Elster,
Exec. VP of Corp. Devel. -
Sean McLennan,
Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer -
Associates, L.L.C.Morenstei...,
-
Target N Vbb Biotech Ag Bio...,
-
Dave Hoffmann,
Director -
Capital Partners Iii, Llc L...,
-
Scott Dcdk Associates, L.L....,
-
Management Services, Llc Cu...,
-
Sean Mc Lennan,
See remarks -
Management Services, Llc Cu...,
-
Gabriela Gruia,
Director -
Maurizio Voi,
Chief Medical Officer